ERBB2 and breast cancer: In this study, we investigated mechanisms of resistance to T-DM1 and T-DXd in HER2+ BC patients and preclinical models and identified potential targets whose inhibition enhances the antitumor activity of T-DXd in HER2-directed ADC-resistant HER2+ BC in vitro and in vivo.